Skip to main content
SpringerLink
Log in

Developing New Drugs for Diabetes and Cardiometabolic Disorders

A Changing Paradigm

  • Editorial
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cefalu WT. Evolving treatment strategies for the management of type 2 diabetes. Am J Med Sci 2012; 343: 21–6

    Article  PubMed  Google Scholar 

  2. Hoerger TJ, Segel JE, Gregg EW, et al. Is glycemic control improving in U.S. adults?. Diabetes Care 2008; 31: 81–6

    Article  Google Scholar 

  3. Chao EC. Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes. Core Evid 2012; 7: 21–8

    Article  PubMed  CAS  Google Scholar 

  4. Mundil D, Cameron-Vendrig A, Husain M. GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. Diab Vasc Dis Res 2012; 9: 95–108

    Article  PubMed  Google Scholar 

  5. Krentz A, Hompesch M. Future drug treatments for type 2 diabetes. Treatment Strategies-Diabetes 2011; 3 (1): 41–9

    Google Scholar 

  6. No authors listed. Lessons from Lipitor and the broken blockbuster drug model. Lancet 2011; 378 (9808): 1976

  7. Krentz AJ. Rosiglitazone: trials, tribulations and termination. Drugs 2011; 71 (2): 123–30

    Article  PubMed  CAS  Google Scholar 

  8. Derosa G, Maffioli P. Anti-obesity drugs: a review about their effects and their safety. Expert Opin Drug Saf 2012; 11: 459–71

    Article  PubMed  CAS  Google Scholar 

  9. O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of Lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM Study. Obesity 2012; 20: 1426–36

    Article  PubMed  Google Scholar 

  10. Chugh PK, Sharma S. Recent advances in the pathophysiology and pharmacological treatment of obesity. J Clin Pharm Ther. Epub 2012 Mar 30

  11. Kramer I, Sauer T. The new world of biosimilars: what diabetologists need to know about biosimilar insulins. Br J Diabetes Vasc Dis 2010; 10: 163–71

    Article  Google Scholar 

  12. No authors listed. Approval of biosimilars in the USA: dead ringers?. Lancet 2012 Feb 25; 379 (9817): 686

Download references

Acknowledgements

The authors and institute have provided contracted clinical research services for pharmaceutical companies that include Astra-Zeneca, Bristol-Myers Squibb, GlaxoSmithKline, Halozyme, Lilly, Novartis, NovoNordisk, Pfizer, Takeda, Wockhardt, Zealand.

Professor Krentz is Visiting Professor of Medicine at the Bedfordshire & Hertfordshire Postgraduate Medical School, Luton, UK.

Author information

Authors and Affiliations

  1. Profil Institute for Clinical Research, Profil Institute for Translational Medicine, 855 3rd Ave, Suite 4400, Chula Vista, CA, 91911, USA

    Andrew J. Krentz, Linda Morrow & Marcus Hompesch

Authors
  1. Andrew J. Krentz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Linda Morrow
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marcus Hompesch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew J. Krentz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krentz, A.J., Morrow, L. & Hompesch, M. Developing New Drugs for Diabetes and Cardiometabolic Disorders. Drugs 72, 1709–1711 (2012). https://doi.org/10.2165/11635550-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11635550-000000000-00000

Keywords

Search

Navigation